Background: The therapeutic action of capsaicin treatment in patients with idiopathic rhinitis (IR) is based on ablation of the transient receptor potential cation channel subfamily V, receptor 1 (TRPV1)-substance P nociceptive signaling pathway. However, the functional consequences of capsaicin treatment on nasal nerve activation and the association between the reduction in nasal hyperreactivity (NHR) and response to capsaicin treatment remain unknown. Objective: We sought to study the effects of capsaicin nasal spray on the afferent innervation of the nasal mucosa by monitoring trigeminal nerve activity in patients with IR and healthy control (HC) subjects. Methods: A double-blind, placebo-controlled randomized trial with capsaicin nasal spray was performed involving 33 patients with IR and 12 HC subjects. Before and at 4, 12, and 26 weeks after treatment, nasal mucosal potentials (NMPs) were measured while exposing the nasal mucosa of patients with IR and HC subjects to aerosols with increasing doses of the chemical irritants allyl isothiocyanate (AITC; also known as
Patients with nonallergic noninfectious rhinitis (NANIR) represent a heterogeneous group, experiencing rhinitis symptoms not caused by allergy or infection. 1 The term idiopathic rhinitis (IR) is used to describe a subgroup of patients with NANIR in which the underlying cause cannot be identified. After exclusion of occupational rhinitis, senile rhinitis (>65 years old), gustatory rhinitis, hormonal rhinitis, and drug-induced rhinitis, it is estimated that 50% of the NANIR group has IR, with an estimated total population incidence of 5%. 1 Nasal hyperreactivity (NHR) is the key clinical feature in the majority of patients with IR, meaning that nasal symptoms like nasal obstruction, sneezing, itch, and/or rhinorrhea can be triggered by environmental factors, such as temperature changes, strong odors, irritants, emotions, and/or physical stress. [2] [3] [4] The pathophysiology of NHR is largely unknown, but it is assumed that local release of neuropeptides, such as calcitonin gene-related peptide, substance P (SP), neurokinin A/neurokinin B, neuropeptide Y, and nerve growth factor (NGF), from afferent nerves on activation of transient receptor potential (TRP) channels induces nasal symptoms. 5, 6 Recently, we have added evidence to the pathophysiologic role of sensory fibers in the pathophysiology of IR and NHR and more specifically of the thermosensitive channels transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) and transient receptor potential cation channel subfamily M, member 8 (TRPM8), which are present on these nerves. 7 We found an overexpression of TRPV1 in patients with IR compared with healthy control (HC) subjects, and our data on the combined reduction of nasal symptoms, NHR, and expression of SP, PGP9.5, TRPV1, and TRPM8 by nasal capsaicin treatment strongly suggests the involvement of the TRPV1-SP nociceptive signaling pathway in patients with IR. 7 Although capsaicin, the pungent agent in chili peppers, is recommended for the treatment of IR, 8 large-scale, double-blind, placebo-controlled trials have not been performed. Furthermore, little is known about prognostic factors influencing the therapeutic outcome of capsaicin nasal treatment. These shortcomings need to be addressed because patients with IR do not respond well to available anti-inflammatory treatment. [9] [10] [11] An in-depth investigation of the neural pathways is an essential step toward a better understanding of the mechanisms of action of capsaicin. In this study we evaluated the functional effects of capsaicin on innervation of the nasal mucosa by measuring nasal mucosal potentials (NMPs) 12, 13 evoked by chemical stimuli in patients with IR before and after capsaicin treatment.
Hummel et al 13 reported on measurements of electrical responses from the nasal respiratory epithelium after painful stimuli with carbon dioxide in human volunteers. NMP responses were interpreted as a summated receptor potential and were restricted to the site of stimulation (ie, the area of activated nociceptors). Further studies served to obtain a topographical map of the sensitivity of the nasal mucosa to trigeminal chemosensory stimuli. [13] [14] [15] In addition to NMP, trigeminal function can be measured based on chemosensory event-related potential, determining the combined function of the trigeminal and olfactory system. 16, 17 However, because of poor signal-to-noise ratio of elicited responses, chemosensory event-related potentials are difficult to assess, and advanced optimizing signal-processing methods are required. 17 In the present study we used NMP measurements 18 for evaluation of the functional (neural) consequences of capsaicin therapy in patients with IR, providing functional insight into the pathophysiology of IR. As a primary aim, we investigated whether the previous findings of overexpression of TRPV1 in nasal biopsy specimens of patients with IR compared with HC subjects 7 had clinical consequences. More specifically, we investigated whether patients with IR were more sensitive to chemical stimuli compared with HC subjects and whether we could find changes in nasal sensitivity after capsaicin treatment, reflecting the state of the nasal innervation. This was measured by recording NMPs on allyl isothiocyanate (AITC) exposure before and at 4, 12, and 26 weeks after capsaicin treatment. As a secondary aim, we investigated whether age, sex, major symptoms, the presence of NHR, or nasal chemical sensitivity had any influence on the outcome.
METHODS

Patients and HC subjects
Thirty-three patients with IR and 12 HC subjects were recruited through the outpatient clinic of the Otorhinolaryngology Department of the University Hospitals of Leuven, Belgium.
Patients with IR were defined as nonsmoking patients with at least 2 nasal complaints of nasal obstruction, rhinorrhea, and/or sneezing for more than 1 hour a day and for more than 1 year; with negative skin prick test (SPT) responses and no clinical signs of infection (discolored secretions); and without anatomic nasal abnormalities responsible for nasal symptoms. Inclusion criteria were as follows: patients with IR between 18 and 65 years old with reported lack of efficacy of nasal corticosteroid treatment at the recommended dose (mometasone furoate, 50 mg per spray 2 times twice daily) for at least 4 weeks who signed the informed consent form. A thorough workup to exclude patients with local allergic rhinitis (LAR) among those with IR included in this double-blind, randomized, placebo-controlled trial was performed in the pilot study of this trial and published previously. 7 In this latter study total IgE levels were measured in the nasal fluid of patients with IR at baseline. 7 Patients with IR were only included if total IgE levels in nasal fluid were less than 5745 kU/L (P90 in HC subjects). The detection limit of total IgE was 2 kU/L. In this pilot study none of the patients with IR included had to be excluded after IgE measurements because levels did not differ from those in HC subjects. 7 In our experience patients with LAR do benefit from intranasal corticosteroids because the underlying pathophysiology is mainly IgE mediated and thus responsive to classic anti-inflammatory treatment. Through exclusive inclusion of patients with nonallergic rhinitis who are ''nonresponsive to intranasal corticosteroids,'' we believe to have indirectly excluded patients with LAR.
Exclusion criteria were a positive SPT response for the 18 most frequent inhalant allergens in Belgium (house dust mite, pollen of timothy grass, smooth meadow grass, orchard grass, nettle, plantago, oxeye daisy, mugwort, alder, birch, hazel, horse, cat, dog, rabbit, and spores of Alternaria, Aspergillus, and Cladosporium species; HAL Allergy, Leiden, The Netherlands), pregnancy or lactation, systemic disorders or malignancies, use of medication affecting nasal function (eg, b-blockers), use of local and/or systemic corticosteroids 4 weeks before the study, and history of prolonged use or abuse of decongestant nasal spray, such as xylomethazoline. Patients with colored secretions, inflammation, or both at the level of the ostiomeatal complex were excluded after nasal endoscopy.
HC subjects were age-and sex-matched, nonsmoking subjects without nasal symptoms and with negative SPT responses. HC subjects did not have anatomic nasal deformities or signs of infection, as evaluated by means of nasal endoscopy.
Nasal medication was prohibited during the entire study.
Study design
The study was registered at ClinicalTrails.gov (NCT01862523) and approved by the Medical Ethical Committee on Clinical Investigations at the University Hospitals of Leuven. Patients with IR and HC subjects were invited for an outpatient visit to the Department of Otorhinolaryngology of the University Hospitals of Leuven at 6 occasions (see Table E1 in this article's Online Repository at www.jacionline.org).
This study was performed in a double-blind, randomized, placebo-controlled way. Patients were randomized in a 2:1 ratio for treatment with either capsaicin or placebo. In HC subjects all examinations were performed in the same way as in patients with IR, but HC subjects did not receive any treatment.
The capsaicin and placebo solutions were prepared by using the formula previously reported by Van Rijswijk et al. 7, 19 In brief, the solution contained capsaicin at 0.1 mmol/L with 30.3 mg of pelargonic acid vanillylamide (capsaicin powder; Sigma-Aldrich, Bornem, Belgium) dissolved in 3 mL of ethanol (96%) and diluted in 1 L of NaCl 0.9% solution. The placebo solution contained the same buffer but lacked pelargonic acid vanillylamide. At the treatment visit, all patients with IR were treated with a blinded nasal spray 5 times on a single day at 1-hour intervals (2 puffs in each nostril, 0.4 mL per puff). The HC group was not treated with capsaicin because previous reporting 7 did not show any differences before and after treatment. The nasal mucosa was anaesthetized before the first 2 applications by using cocaine 5% nasal spray (same volume per spray as mentioned above). To ensure effective local anesthesia, an interval of 15 minutes was maintained between the cocaine and blind nasal spray application.
The power analysis (power of 80%) to determine the sample size, which was conducted before the start of the trial, revealed a number needed to include of at least 33 patients with IR. This calculation was based on a 2-sided x 2 test (with an a value of 5%) with unequal group size (one third placebo and two thirds capsaicin). The success rate of capsaicin was assumed to be 75% based on the results of the previous trial conducted at our institution. 7 Success was defined as a decrease of at least 30% on the visual analog scale (VAS) for the major nasal symptom. The estimated placebo effect was 25%.
Evaluation of nasal symptoms
All participants were asked to mark the typical nasal symptoms of IR (ie, rhinorrhea, nasal obstruction, itch, and sneezing) on a VAS scale (0-10) at the screening visit (visit 1), baseline visit (visit 2), and follow-up visits: follow-up 1 (visit 4 at week 4), follow-up 2 (visit 5 at week 12), and follow-up 3 (visit 6 at week 26). Only if the VAS score was greater than 2 for one of the nasal symptoms was the symptom considered relevant. The major nasal symptom was selected based on the highest VAS score at screening. The total symptom score (TSS) was the sum of the VAS scores for rhinorrhea, nasal obstruction, sneezing, and itch. At visits 4, 5, and 6, a therapeutic response evaluation (TRE) was performed. Patients with IR were asked to score the overall improvement of their symptoms compared with baseline (0 5 total reduction or symptom-free, 1 5 major reduction, 2 5 moderate reduction, 3 5 minor reduction, and 4 5 no reduction of symptoms).
Subjective NHR
At the screening visit, each patient with IR and HC subject was asked to evaluate their NHR. Subjects had to answer the following question: ''Can your nasal symptoms be triggered by temperature changes and/or strong odors?'' If the answer was yes, they had to indicate how long the symptoms lasted. If the induced symptoms lasted for more than 5 minutes, we defined these patients as having NHR. Short-term (< _ 5 minute) induction of nasal symptoms, such as rhinorrhea, after sudden temperature changes were not considered NHR.
Measurement of NMPs during nasal chemical stimulations
Trigeminal nerve monitoring was performed while the nasal mucosa was exposed to TRP channel agonists to investigate the role of afferent fibers in the human nasal mucosa in a functional way. We used capsaicin as a specific TRPV1 agonist and AITC, which is also known as mustard oil, as an agonist of both transient receptor potential cation channel subfamily A, receptor 1 (TRPA1) and TRPV1. 20 During exposure of the nasal mucosa to the different substances, NMPs were recorded on the nasal floor of the left nostril at a depth of 5 cm, as described previously. 12, 13 In brief, NMP recordings were performed with an 8-French nasogastric tube filled with 3% agar in Ringer solution connected to a calomel electrode through a saturated KCl bath. The position of the catheter was controlled by means of anterior rhinoscopy, and the catheter was taped to the nose to obtain a stable position during recording. The skin reference electrode was attached to the bridge of the nose. Both electrodes were connected to a bioamplifier (BMA-200; ADInstruments, Colorado Springs, Colo) through a headstage (IS0-Z isolation headstage, ADInstruments). Data were acquired at a frequency of 50 Hz by using a PowerLab device (Powerlab 4/30, ADInstruments) and LabChart software (version 7.0, ADInstruments). For stimulation, TRP channel agonists were administered through an intranasal aerosol in increasing concentrations (5, 10, and 20 mmol/L dissolved in Ringer solution at room temperature). Concomitant mechanical or thermal stimulation was absent by using this application form, and the flow used (1.5 L/min) corresponded to physiologic conditions. The sequence of testing the different stimuli was fixed, starting with AITC and ending with capsaicin. An interval of 2 to 3 minutes was left between stimuli. Maximal stimulus duration was 30 seconds or less if not tolerated (pain) by the subject.
Between the different stimulations with TRP channel agonists, a continuous aerosol with control solution (Ringer solution) was delivered. The multichannel aerosol device was placed behind the patient, and therefore the patient could not anticipate the stimulus. The stimulus threshold was determined by the lowest concentration at which there was a clear and fast (<10 seconds) deflection in the NMP recording. The deflection was considered positive when the negative deflection of the trace surpassed 5 times the SD of the baseline measurement. This threshold was determined for every subject at baseline and each follow-up visit. Both patients with IR and HC subjects underwent NMP measurements at different time points (see Table E1 ).
A change in threshold was defined according to a decrease or increase in threshold concentration compared with baseline. In the Figures, this change (increase of 1 or 2 concentrations compared with baseline concentration for each subject) is used to visualize the relation with VAS major symptom scores and TSSs.
Collection of nasal biopsy specimens
Before treatment and at 4 and 26 weeks after treatment, a nasal biopsy specimen was taken from the inferior turbinate with a Fokkens forceps, as reported earlier. 7 The biopsy specimen was snap-frozen in liquid nitrogen and stored at 2808C for quantitative real-time PCR (RT-PCR).
RT-PCR for TRPV1, TRPA1, TRPV4, TRPM8, PGP9.5, and NGF on nasal biopsy specimens consisting of purified plasmid DNA specific for each individual target, were used to quantify the target gene in the unknown samples, as described before. 7 The primer and probe sequences were designed with Primer Express (Applied Biosystems).
Statistical methodology
The results of the VAS measurements and TREs, AITC thresholds, and RT-PCR data were compared by using the Mann-Whitney U test. The Bonferroni-Holm method was applied to correct for multiple comparisons. All analyses were performed on available cases; hence it was assumed that data were missing completely at random. This assumption was plausible because all missing values were purely due to logistical problems. The Zelen exact test was used to verify whether the effect of capsaicin differed between groups (NHR vs no NHR; AITC < _ 5 mmol/L and 10 < _ AITC < _ 20 mmol/L). A difference was considered significant at a P value of less than .05. Values displayed represent means 6 SEMs. For the RT-PCR data, a geometric mean of the 2 reference genes was calculated to have an accurate normalization. Analyses were performed with GraphPad Prism program (version 4.03, Prism 4; GraphPad Software, San Diego, Calif).
RESULTS
Baseline characteristics of patients with IR and HC subjects
Patients with IR and HC subjects showed no major differences with respect to age distribution (IR group, 41 years [19-63 years] ; HC group, 29 years [19-57 years]) or race (all white), as shown in Table I . Within the IR group, there were no significant differences between the capsaicin-and placebo-treated cohorts regarding age, sex, or race. The female/male ratio was 18/15 in patients with IR and 6/6 in HC subjects. All subjects had negative SPT responses for the 18 most frequent inhalant allergens in Belgium and showed no endonasal anatomic or mucosal signs of rhinosinusitis. Forty-two percent (n 5 14) of patients with IR had been operated in the past to improve their nasal symptoms (eg, septoplasty or reduction of the inferior turbinate) without a self-reported significant effect on nasal symptom reduction. Fifty-seven percent (n 5 19) of all included patients with IR had self-reported NHR.
VAS scores
At baseline, nasal obstruction was reported as a major symptom by 21 patients, rhinorrhea by 10 patients, nasal itch by 1 patient, and sneezing by 1 patient (Table I ). The mean baseline VAS major symptom score was 8.2 6 1.9 cm. There were no major baseline differences in symptom scores between the capsaicin-and placebo-treated patients with IR. HC subjects were symptom free at baseline and remained so throughout the study (data not shown).
mRNA expression of TRPV1, PGP9.5, TRPA1, TRPV4, TRPM8, and NGF Baseline mRNA expression of TRPV1 was significantly higher in patients with IR compared with HC subjects (P 5 .031), as shown previously.
7 TRPV1 expression in patients with IR with NHR showed a trend to be higher than in patients with IR without NHR (P 5 .2903). Expression levels of the panneuronal marker PGP9.5, the cation channels TRPV4 and TRPM8, and the neurotrophic factor NGF were not different between patients with IR and HC subjects at baseline (P 5 .274, P 5 .497, P 5 .370, and P 5 .781, respectively). For TRPM8, two thirds of the samples had very low mRNA expression levels and had to be excluded. TRPA1 mRNA could not be detected.
Lower baseline threshold for TRPV1/TRPA1-mediated activation of sensory nerves in patients with IR
To objectively and functionally assess the baseline observation of TRPV1 overexpression in patients with IR compared with HC subjects, we evaluated the chemical sensitivity of the afferent nerves in the nasal mucosa with NMP measurements during exposure to different TRP channel agonists in increasing concentrations. The threshold was determined for each subject. AITC (a TRPV1 and TRPA1 agonist) turned out to be the best stimulus. This was because capsaicin (a specific TRPV1 agonist) often induced coughing, thereby disturbing the NMP measurement.
At baseline, the threshold for evoking changes in NMPs by AITC was significantly lower for patients with IR compared with HC subjects (P 5 .0423; Fig 1, A-C) . Consecutive NMP measurements in the HC and IR groups treated with placebo at different time points stayed stable; data from HC subjects are not shown. Patients with self-reported NHR had lower AITC thresholds compared with patients with IR without NHR (P 5 .0335; Fig 1, D) .
Clinical improvement of patients with IR after capsaicin treatment
Compared with baseline, VAS scores for nasal obstruction, rhinorrhea, and itch decreased significantly 4, 12, and 26 weeks after capsaicin treatment, whereas no significant decrease was seen after placebo treatment (Fig 2, C-F) . For sneezing, no significant changes were observed after treatment; however, only a few patients reported sneezing as symptoms (n 5 7/33). Sneezing is a more typical symptom in patients with allergic rhinitis than in patients without allergic rhinitis/patients with IR. VAS scores for major symptoms were also significantly reduced at 4, 12, and 26 weeks after capsaicin treatment (P 5 .2007, P 5 .0081, and P 5 .0217, respectively), as were TSSs (P 5.0064, P 5.0167, and P 5.01468, respectively). These changes were not observed in the placebo group (Fig 2, A and B) . The TRE yielded clear changes in the distribution of capsaicintreated patients toward reduction of symptoms after 4, 12, and 26 weeks, which was not observed in the placebo-treated patients (P 5.0192, P 5.0045, and P 5.0155; Fig 3) . Sixty-eight percent, 81%, and 72% of patients with IR treated with capsaicin reported improvement (score, 0-3) at 4, 12, and 26 weeks, respectively. Major improvement (score, 0-2) was reported by 45%, 48%, and 50%, respectively. Only 1 patient with IR treated with placebo reported moderate improvement after 4 weeks, and 2 patients reported improvement after 12 weeks. At 26 weeks, none of the patients in the placebo group reported improvement. The TSS in the HC group was 2.1 6 0.5 at baseline.
Capsaicin treatment increased the threshold for sensitivity to AITC in correlation with an improvement in symptom scores
In the IR group treated with capsaicin, the threshold for AITC shifted toward significantly higher concentrations at 4 and 12 weeks after treatment compared with the placebo-treated IR group (P 5 .0406 at 4 weeks, P 5 .0325 at 12 weeks, and P 5 .0611 at 26 weeks; Fig 4) . The ''degree'' of shift in threshold, reflecting the reduction in nasal sensitivity to a chemical stimulus, correlated significantly with the change/improvement in TSSs (r 5 0.604, P 5.0018; Fig 5, A) and VAS major symptom scores (r 5 0.714, P 5 .0004; Fig 5, B) (Fig 4; 12 on  Fig 5, B) . This demonstrates that patients with pronounced nasal sensitivity to AITC are very good responders to capsaicin (Fig 6, B) .
Capsaicin treatment induced no reduction in PGP9.5, TRPV1, TRPV4, TRPM8, and NGF expression in patients with IR 4 and 26 weeks after treatment Expression levels of the panneuronal marker PGP9.5 were not different between patients with IR and HC subjects at baseline and did not change after treatment (data not shown). The same was observed for TRPV4 and TRPM8. Although we found a significant overexpression of TRPV1 in patients with IR (Fig 1, A) and a patient with IR (Fig 1, B) . C, Distribution of HC subjects and patients with IR according to the concentration threshold for NMP responses to AITC. D, Distribution of patients with IR with and without NHR according to the concentration threshold for NMP responses to AITC. *P < .05.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 2 compared with HC subjects at baseline (P 5 .0313; Fig 7, A) , no significant decrease was observed after capsaicin treatment. mRNA levels of TRPA1 were less than the detection limit in the IR and HC groups (data not shown). Nasal biopsy specimens of patients with IR and control subjects had similar expression of NGF mRNA before and after treatment (data not shown).
Baseline human TRPV1 expression correlated with results of TRE 12 weeks after capsaicin treatment
Patients with IR with high baseline TRPV1 expression showed a better response to capsaicin treatment (TRE showed moderate improvement until symptom free) compared with patients with IR with median or low TRPV1 expression, which showed only a minor improvement or no improvement, respectively (P 5 .024; Fig 7, B) . (Fig 2, A) and average VAS scores for major symptoms at baseline and at 4, 12, and 26 weeks after capsaicin or placebo treatment in patients with IR (n 5 24 and n 5 9, respectively). C-F, Average VAS scores for individual symptoms at 4, 12, and 26 weeks after capsaicin or placebo treatment in patients with IR. The maximum of the scale for TSSs and VAS scores for major symptom/individual symptoms were 40 and 10 cm, respectively. *P < .05 and **P < .005.
Self-reported NHR can be a promising predictor of capsaicin treatment efficacy in patients with IR
In the capsaicin-treated patient cohort, 63% reported subjective NHR. Patients with IR with self-reported NHR showed a clear trend to be better responders to capsaicin treatment compared with patients with IR without self-reported NHR (P 5 .10, Zelen exact test) 12 weeks after treatment (Fig 6, A) . Capsaicin-treated patients with IR with low baseline AITC thresholds had better TREs compared with patients with IR with high baseline AITC thresholds (Fig 6, B) , although without reaching significance. Age, sex, and baseline major symptom score had no significant influence on TRE (data not shown).
DISCUSSION
Here we provide novel insight into the pathophysiology of IR by functional measurements of neural responses before and after capsaicin treatment. Our data strongly support the involvement of the TRPV1 and TRPA1 nociceptors in the pathophysiology of IR. First, we found an increased nasal chemical sensitivity to the TRPA1 and TRPV1 agonist AITC in patients with IR, and second, we found that both the sensitivity to AITC and the IR symptoms decreased after capsaicin treatment. Baseline overexpression of TRPV1 (RT-PCR) in combination with increased chemical sensitivity in patients with IR shows the crucial role of the TRPV1-SP nociceptive signaling pathway in IR pathophysiology, both structurally and functionally, as previously suggested. 7 The correlation between the reduction of symptoms (VAS major symptoms and TSSs) and the degree of decrease in chemical sensitivity to AITC underlines the reliability and relevance of the functional data.
The therapeutic response to capsaicin was not associated with a clear decrease in TRPV1 expression, as previously reported. 7 In contrast to the previous study, 7 NHR was not an inclusion criterion, and the IR cohort reported here included patients with IR with and without NHR, with no significant overall decrease of TRPV1 after capsaicin treatment. Of note, self-reported NHR seems to be a potential prognostic factor for a good therapeutic response to nasal capsaicin treatment. In addition, the moment of harvesting the nasal biopsy specimens after treatment was different (at 4 and 26 weeks after treatment compared with 12 weeks in the previous report). At 26 weeks, reinnervation might be present, which could explain the recurrence of symptoms at this time point in some patients and also corresponds to the return of the threshold for AITC detection to baseline levels (Fig 4) . At 4 weeks, the maximal therapeutic effect is not yet reached, as shown by the individual symptom reduction and TRE (Fig 3) .
The strength of this study lies within the functional neuronal readout. Based on our previous findings, 7 we wanted to investigate the role of the chemosensory TRP channels in more depth. [20] [21] [22] For this, we built a multichannel aerosol device with the possibility to apply several compounds in sequence. This, in combination with measurement of changes in NMPs, allowed us to estimate the concentration thresholds of the responses to the TRPA1 and TRPV1 agonist AITC. A comparable technique to measure mucosal potentials was already used and validated in 1993 by Th€ urauf et al. 12 Our method of intranasal application by the multichannel aerosol is more patient friendly than the nasal lavages with TRP agonists described before by Alenmyr et al. 5 Our study demonstrates an increased chemical sensitivity in patients with IR compared with HC subjects at baseline and ''normalization'' after capsaicin treatment. At present, we can only speculate on the mechanisms underlying the differences in baseline chemical sensitivity between patients with IR and HC subjects. Retrospective analysis of our files from patients with IR revealed a previous nasal fracture in almost one third of them, suggesting a potential aberrant reinnervation after trauma of the nasal mucosa. This hypothesis needs further study.
Interestingly, our data suggest a better capsaicin treatment response in patients with self-reported NHR compared with patients with IR without a history of NHR (Fig 6, A) . Unfortunately, because of the small number of patients in the subgroup analysis, only a clear trend could be observed, but this observation is of tremendous clinical value because a history of NHR is a clinical parameter during history taking, with a seemingly high predictive value for a therapeutic effect of capsaicin. In addition, this observation matches with the clinical finding that patients with more pronounced NHR (threshold of AITC of 5 mmol/L) respond better to capsaicin therapy compared with patients with IR with a higher threshold (AITC 20 mmol/L; Fig 6, B) . These data suggest that although our inclusion criteria for patients with IR were very strict, the cohort is still heterogeneous regarding functional properties and features of the nasal afferent innervation. Only the broad TRPV1 baseline expression in patients with IR is in line with this assumption. Nevertheless, the correlation between increased baseline TRPV1 expression and good TRE strongly supports the role of TRP channels (Fig 7) in capsaicin treatment effects. As for future clinical practice, baseline measurements of NHR by means of cold dry air provocation or chemical stimulation could be recommended before capsaicin treatment to predict the therapeutic outcome. Recent findings showed that objective NHR measurements (eg, cold dry air challenge) were more sensitive compared with self-reported NHR (Van Gerven et al, unpublished data) and would therefore be superior in the pretreatment setting.
Since our first experience with capsaicin treatment more than 10 years ago, we repeated nasal treatment in the majority of responders several times, with a variable interval between capsaicin treatments ranging from 6 months to several years. This phenomenon of recurrent symptoms prompted us to study the mechanisms of recurrence of symptoms in a functional way by recording NMPs. Lacroix et al 23 reported on the beneficial effects up to 6 months after capsaicin treatment, and Van Rijswijk et al 19 reported on this up to 9 months. However, no studies were specifically designed to investigate the exact duration of the therapeutic response or to investigate the mechanisms underlying this phenomenon. We found a decreased sensitivity to AITC early after capsaicin treatment and restoration of the sensitivity at 6 months. In contrast to NMP recordings at 6 months after nasal capsaicin treatment, symptom severity was still lower at 6 months compared with baseline. The discrepancy between symptom recurrence and reinnervation might be linked to the fact that full neural functional recovery can take longer than 6 months.
In conclusion, for the first time, we show functional evidence for increased chemical sensitivity in patients with IR compared with HC subjects, reflecting the state of the nasal afferent innervation and the important role of the nociceptors TRPV1 and TRPA1 in the pathophysiology of IR. Moreover, we demonstrate a clear decrease in sensitivity and symptoms after capsaicin treatment, revealing at least part of the (Fig 5, A) and VAS scores for major symptoms (Fig 5, B) determined 4 weeks after capsaicin treatment. C and D, Examples of NMP responses to AITC recorded in a patient with IR before (Fig 5, C) and 4 weeks after (D-F) capsaicin treatment. Note the sharp negative deflection of the trace in response to application of 5 mmol/L AITC before treatment, and the lack of such a response 4 weeks after treatment even at 20 mmol/L AITC.
working mechanism of this therapeutic agent. Finally, we found self-reported NHR to be a potential predictor for capsaicin treatment efficacy. In the future, NHR might be assessed before capsaicin treatment to select patients more likely to respond.
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